Memorial Sloan Kettering Cancer Center

The FDA has approved the drug zanidatamab to treat advanced and metastatic bile duct cancer and other biliary tract cancers that have high levels of a protein called HER2 and do not respond to chemotherapy. Dr. James Harding, a gastrointestinal medical oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center (MSK), led the trial that resulted in the drug's approval. “These cancers are rare, making up just 3% of all gastrointestinal cancers,” Dr. Harding says. “But MSK is a major center for biliary tract cancer research and treatment. We are evaluating multiple novel treatment approaches, and a key focus of our work is on molecular testing of these tumors and finding ways to target them with precision medicine.” Learn more: https://bit.ly/3OoWBJO

Why are young and middle-aged women getting diagnosed with lung cancer at higher rates than men, even if some have never smoked before? MSK thoracic medical oncologists Dr. Helena Yu and Dr. Alexander Drilon discuss potential reasons why lung cancer rates are rising in women and the need to research more targeted therapies. CNN Learn more ⬇️

A group of thoracic oncology experts at Memorial Sloan Kettering Cancer Center (MSK) wore white to bring awareness to lung cancer awareness month and support those living with lung cancer.

New research from Memorial Sloan Kettering Cancer Center (MSK) investigates how pancreatic cancer cells regulate their genome to avoid immune attack; shows promise against glioblastoma in mouse models; and develops a new method to study cancer evolution. Learn more: https://lnkd.in/eUrqAzEc

Memorial Sloan Kettering’s mission of ending cancer for life is a bold one, but vital to anyone experiencing a cancer diagnosis. We depend on collaboration from health insurers to continue this mission, but Anthem BCBS has been ignoring what it takes to deliver MSK’s exceptional care. MSK board member John Strangfeld shares how MSK is working hard to come to an agreement with Anthem. Read more: https://njersy.co/4i0vFNT

Twenty-nine researchers from Memorial Sloan Kettering Cancer Center (MSK) and the Sloan Kettering Institute (SKI) are on Clarivate's Highly Cited Researchers 2024 list, demonstrating significant influence in their chosen field by publishing multiple Highly Cited Papers™ in their areas of expertise in the past decade. Their papers are ranked in the top 1% by citations for their field and year. Some of the researchers include Dr. Mark Awad, Dr. Luis Diaz, Dr. Alexander Drilon, Dr. Jonathan Rosenberg, and Dr. Eileen O’Reilly. View the full list below, and please join us in celebrating our colleagues in the comments 👏 https://bit.ly/3CMDiax

The FDA has approved revumenib for patients 1-year-old and older who have leukemia that has come back after treatment and whose cancer carries a molecular change called a KMT2A translocation. Dr. Eytan Stein, an expert in early drug development and Chief of the Leukemia Service at Memorial Sloan Kettering Cancer Center (MSK), led the trial that brought about the drug's approval. Revumenib is the first drug in a new class called menin inhibitors to receive FDA approval. Learn more: https://bit.ly/3V0eBxV

Dr. Joan Massagué, Director of the Sloan Kettering Institute (SKI) and Chief Scientific Officer for Memorial Sloan Kettering Cancer Center (MSK), is known for his research in cancer biology. A lesser known place where Dr. Massagué is in his element outside of a research lab: among fellow rockhounds enchanted by the beauty of crystals. At its most expansive, Dr. Massagué’s collection numbered over 1,000 specimens. Today, it’s down to a trim 400 — most of them measuring just a few inches. These he keeps on display at his home in glass-fronted cabinets. Both his work as a biologist and as a rock hunter involve painstaking detective work. “It requires patience,” Dr. Massagué says. “There’s no right or wrong. There is no one style. Just like with the SKI, I’m interested in letting the component parts help each other — so that the whole becomes more than the sum of the parts.” Read more about Dr. Massagué: https://bit.ly/4eHHdmz

Looking to make the next groundbreaking discovery in cancer and biomedical sciences? The Gerstner Sloan Kettering Graduate School of Biomedical Sciences at Memorial Sloan Kettering Cancer Center is accepting applications for their Cancer Biology and Cancer Engineering programs. The deadline to apply is Sunday, 12/1. Apply now: https://bit.ly/4fnQ4uJ

Join thoracic oncology experts from Memorial Sloan Kettering Cancer Center (MSK) this weekend at the NY Lung Cancers Symposium, including Dr. Helena Yu, Dr. Alexander Drilon, Dr. Gregory Riely, and more as they speak about the latest in lung cancer treatment and research. Learn more here: https://bit.ly/4ewpNZNCon